TransCure bioServices partners with Preclina to expands reach into APAC
Biotech

TransCure bioServices partners with Preclina to expands reach into APAC

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders

  • By IPP Bureau | July 26, 2023

TransCure bioServices, a humanized mouse model CRO, has partnered with Preclina Inc., a South Korean preclinical CRO specializing in autoimmune and inflammatory diseases.

The partnership significantly expands TransCure’s reach into the APAC region, while also bolstering its service offerings to further enhance the quality of its research results. Biotechnology and pharmaceutical companies in the region will now have better access to a selection of the most advanced mouse models, as well as the full suite of services required for optimized preclinical development — capabilities that have been challenging to access in the region until now.

The partnership between TransCure bioServices and Preclina directly addresses these challenges, providing APAC customers with the full suite of advanced preclinical services under one umbrella, as well as the most advanced, internationally recognized mouse models and cell lines to help optimize and streamline their preclinical programs.

"TransCure’s one-stop-shop offering spans three platforms, more than 50 proven animal models, and a vast selection of technical services," said Kiave Ho Wang Yin, PhD, Chief Business Officer at TransCure bioServices. "By joining forces with Preclina, we further bolster those offerings with extensive autoimmune and inflammatory disease expertise, unlocking new insights for APAC-based developers, while bringing our renowned partnership-rather-than-supplier approach to the region. With this foothold, we’re uniquely positioned to grow our capacity in the region and further innovate for the benefit of our sponsors."

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders, such as NASH, fibrosis, arthritis, and scleroderma. It boasts extensive knowledge in immunology, with expertise in patient-derived cells and animal models that faithfully recapitulate these disorders.

"Combining our know-how and services with TransCure’s offers a unique opportunity to better address the preclinical needs of APAC customers," said Young Mo Kang, PhD, CEO at Preclina. "We’re delighted that this partnership will further augment the high-quality, comprehensive services we’re well known for. We look forward to delivering the fruits of this collaboration to our customers, helping them carve a smoother route to better preclinical research for transformative therapeutics and diagnostics."

Upcoming E-conference

Other Related stories

Startup

Digitization